short acting glp 1 agonists GLP-1 and Diabetes Mellitus A Comprehensive Review of the

Retatrutide NAFLD: phase 2 trial results in subset of patients with obesity and NAFLD

Its who will be positioned to lead and who will be disrupted

Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing

June 2, 2024

The result is a pattern that looks new but is, physiologically, familiar: deficiency-driven, stress-driven hair thinning

Human clinical trials, though limited, have demonstrated a potential decrease in substance use among patients treated with GLP-1RAs, particularly for alcohol and tobacco use disorders